FDA details flexibilities for new cell and gene therapies to leverage past data
The FDA is further explaining to cell and gene therapy developers the types of prior knowledge companies can leverage for clinical, nonclinical and manufacturin...
The FDA is further explaining to cell and gene therapy developers the types of prior knowledge companies can leverage for clinical, nonclinical and manufacturing-related work, according to new CBER draft guidance released Tuesday. Building off ...